Agios Pharmaceuticals
AGIO
164 hedge funds and large institutions have $1.36B invested in Agios Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 58 reducing their positions, and 13 closing their positions.
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
3% more funds holding
Funds holding: 160 → 164 (+4)
1.17% more ownership
Funds ownership: 105.28% → 106.45% (+1.2%)
3% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 58
16% less capital invested
Capital invested by funds: $1.62B → $1.36B (-$268M)
44% less call options, than puts
Call options by funds: $4.85M | Put options by funds: $8.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$18.9M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$11.4M |
| 3 |
Nordea Investment Management
Stockholm,
Sweden
|
+$8.14M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.92M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$5.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$43.4M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$22.2M |
| 3 |
Goldman Sachs
New York
|
-$15.9M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$8.9M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$6.16M |
AGIO Hedge Fund Activity: Q1 2023 in Review
164 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2023, worth a combined $1.36B — down 16% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AGIO positions and 13 closed out — a net gain of 5 holders — while 60 added to existing stakes and 58 trimmed.
The largest buyer was Armistice Capital, adding an estimated $18.9M. The largest seller was Fidelity Investments, cutting an estimated $43.4M.
- 164 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2023, up from 160 in Q4 2022.
- Funds reported $1.36B of Agios Pharmaceuticals stock for Q1 2023, down 16% quarter-over-quarter.
- 18 funds opened new Agios Pharmaceuticals positions in Q1 2023 and 13 closed out, a net change of +5 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2023 was Armistice Capital, an estimated $18.9M added.
- The largest Agios Pharmaceuticals seller in Q1 2023 was Fidelity Investments, an estimated $43.4M sold.
Based on aggregated 13F filings for Q1 2023.